C12N 2760/10032
Use of virus as therapeutic agent, other than vaccine
Official title: Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
C12N2760/10032 (Use of virus as therapeutic agent, other than vaccine) appears on 13 US grants and 16 published applications in this corpus.
Search patents in C12N- Granted patents
- 13
- Published applications
- 16
- Assignees
- 4
- Inventors
- 19
- Latest grant
- 18 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2010 | 0 | 1 |
| 2011 | 0 | 1 |
| 2012 | 0 | 0 |
| 2013 | 1 | 0 |
| 2014 | 0 | 1 |
| 2015 | 0 | 0 |
| 2016 | 1 | 1 |
| 2017 | 1 | 1 |
| 2018 | 2 | 1 |
| 2019 | 0 | 3 |
| 2020 | 1 | 0 |
| 2021 | 0 | 1 |
| 2022 | 2 | 3 |
| 2023 | 1 | 0 |
| 2024 | 1 | 1 |
| 2025 | 2 | 2 |
| 2026 | 1 | 0 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Virus particles for therapeutic purposes18 Aug 2026US 12,708,654 B2Abalos Therapeutics GmbH
- Administering a lymphocytic choriomeningtitis virus (LCMV) with improved tumor regression properties9 Sep 2025US 12,409,217 B2Abalos Therapeutics GmbH
- Replication-defective arenavirus vectors18 Feb 2025US 12,227,755 B2UniversitäT ZüRich
- Method for producing an antitumoral arenavirus as well as arenavirus mutants29 Oct 2024US 12,129,281 B2Abalos Therapeutics GmbH
- Method of enhancing innate immune responses against a tumor comprising administering lymphocytic choriomeningitis virus (LCMV)31 Oct 2023US 11,801,294 B2Abalos Therapeutics GmbH
- Replication-defective arenavirus vectors4 Dec 2025US 2025/0369015 A1UniversitäT ZüRich
- Method for producing an antitumoral arenavirus as well as arenavirus mutants17 Apr 2025US 2025/0122244 A1Abalos Therapeutics GmbH
- Arenaviruses for use in the treatment and/or prevention of tumors and method for producing arenaviruses with (im-proved) tumor-regression properties1 Aug 2024US 2024/0252611 A1Abalos Therapeutics GmbH
- Replication-defective arenavirus vectors6 Oct 2022US 2022/0315951 A1UniversitäT ZüRich
- New virus particles for therapeutic purposes1 Sep 2022US 2022/0273741 A1Abalos Therapeutics GmbH
Most cited
By later US patents
- Replication-defective arenavirus vectors17US 8,592,205 B2UniversitäT ZüRich · 2013
- Replication-defective arenavirus vectors13US 9,309,289 B2UniversitäT ZüRich · 2016
- Replication-defective arenavirus vectors11US 9,944,952 B2UniversitäT ZüRich · 2018
- Replication-defective arenavirus vectors4US 10,655,145 B2UniversitäT ZüRich · 2020
- Replication-defective arenavirus vectors1US 11,401,528 B2UniversitäT ZüRich · 2022